8-K: Abacus Life Announces Preliminary Q3 2024 Results: Revenue Growth and Strategic Acquisitions Highlight Quarter

Abacus Life reports preliminary Q3 2024 results, projecting revenue between $26 and $28 million and adjusted EBITDA between $14 and $16 million, alongside strategic acquisitions and management team expansions.

Summary

• Abacus Life has released preliminary unaudited financial results for the third quarter of 2024, ended September 30.
• The company anticipates total revenue to be between $26.0 and $28.0 million, representing a year-over-year growth of 23-33%.
• GAAP net income is expected to be between a loss of $6.0 and $6.75 million, primarily due to a non-cash increase in warrant liability of $8.0 to $9.0 million.
• Adjusted EBITDA is projected to be between $14.0 and $16.0 million, showing a year-over-year growth of 30-48%.
• The company announced key acquisitions of Carlisle Management Company SCA and FCF Advisors during the quarter.
• Abacus also strengthened its management team with the addition of Corey McLaren as Managing Director of Capital Markets and Robert F. Phillips as Senior Vice President of Investor Relations and Corporate Affairs.
• They partnered with Lorisco to launch PREADISAN, a health prediction and actuarial technology tool.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue and EBITDA growth, strategic acquisitions, and new technology partnerships. However, the net loss due to warrant liability and the preliminary nature of the results temper the overall sentiment.

Positives

• The company is experiencing strong revenue growth, with a projected increase of 23-33% year-over-year.
• Adjusted EBITDA is also showing significant growth, with an expected increase of 30-48% year-over-year.
• Strategic acquisitions of Carlisle Management Company SCA and FCF Advisors are expected to contribute to future growth.
• The addition of key personnel is expected to strengthen the management team.
• The launch of PREADISAN is expected to enhance the company's technological capabilities.

Negatives

• The company is projecting a net loss for the quarter, primarily due to a non-cash increase in warrant liability.
• The preliminary nature of the results means that the final figures may vary materially.

Risks

• The preliminary financial results are subject to change as the company's financial closing procedures are not yet complete.
• The company's loss reserves are based on estimates and may be inadequate to cover actual losses.
• There is a risk of failure to properly price insurance policies.
• The company is exposed to risks related to the cyclical nature of its industry and the impact of regulation.
• The company faces competition and risks related to its relationships with independent agencies.
• There is a risk of failure to meet investment objectives and the inability to raise capital on favorable terms.
• The company is exposed to the effects of acts of terrorism and the effectiveness of its control environment.

Future Outlook

The company remains committed to executing on its long-term growth initiatives and delivering value to its shareholders. They will release full financial statements for the three months ended September 30, 2024, at a later date.

Management Comments

• Jay Jackson, Chief Executive Officer of Abacus, stated that they are pleased to report another strong performance across their business.
• He also highlighted the clear differentiation of their business model.
• He expressed excitement about the acquisitions of Carlisle Management Company SCA and FCF Advisors.
• He noted the strengthening of the management team with the addition of Corey McLaren and Robert F. Phillips.
• He mentioned the partnership with Lorisco to launch PREADISAN.

Industry Context

Abacus Life operates in the alternative asset management sector, specializing in lifespan-based financial products. The company's focus on longevity and actuarial technology positions it within a growing market segment. The acquisitions and technology partnerships suggest a strategy to expand market share and enhance product offerings.

Comparison to Industry Standards

• Abacus Life's focus on lifespan-based financial products is relatively unique compared to traditional asset managers like BlackRock or Vanguard, which primarily focus on stocks and bonds.
• The company's adjusted EBITDA growth of 30-48% year-over-year is strong compared to the average growth rates of many financial services companies, which often range from 5-15%.
• The non-cash warrant liability impact on net income is a common issue for companies with complex capital structures, and the magnitude of $8-9 million is significant but not unusual for a company of this size.
• The launch of PREADISAN is a unique offering compared to competitors, potentially giving Abacus a competitive edge in longevity forecasting and tailored financial solutions.
• Companies like GWG Holdings, which also focused on life insurance assets, have faced challenges, highlighting the importance of risk management and proper pricing in this sector.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the revenue and EBITDA growth, but negatively to the net loss.
• Employees may be positively impacted by the company's growth and strategic initiatives.
• Customers may benefit from the new technology and tailored financial solutions.
• Suppliers and creditors may see the company as a stable and growing partner.

Next Steps

• Abacus Life will release its full third quarter 2024 financial results after the market closes on Thursday, November 7, 2024.
• Management will hold a conference call to discuss the financial results at 5:00 pm Eastern Time on November 7, 2024.

Key Dates

Keywords

Abacus Life, Financial Results, Q3 2024, Revenue, EBITDA, Acquisitions, Life Insurance, Longevity, Alternative Asset Management, PREADISAN